{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:04:59Z","timestamp":1751601899393,"version":"3.41.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["DBT\/2019\/CDRI\/1280"],"award-info":[{"award-number":["DBT\/2019\/CDRI\/1280"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSIR Fundings"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02803-4","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:44:19Z","timestamp":1749239059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gilteritinib suppresses prostate cancer cell proliferation and migration and induces ER stress-mediated non-autophagic cytoplasmic vacuolization cell death"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9292-5302","authenticated-orcid":false,"given":"Gaurav","family":"Jha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-7582","authenticated-orcid":false,"given":"Bhawna","family":"Tomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5829-5134","authenticated-orcid":false,"given":"Sakshi","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-3998","authenticated-orcid":false,"given":"Divyansh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3624-7908","authenticated-orcid":false,"given":"Radhika","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-3478","authenticated-orcid":false,"given":"Sonam","family":"Kanchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-3993","authenticated-orcid":false,"family":"Sushma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-0533","authenticated-orcid":false,"given":"Srikanta Kumar","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"2803_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"2803_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63\u201389. https:\/\/doi.org\/10.14740\/wjon1191.","journal-title":"World J Oncol"},{"key":"2803_CR3","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.","journal-title":"Molecules"},{"key":"2803_CR4","first-page":"306","volume":"12","author":"K Tangirala","year":"2019","unstructured":"Tangirala K, Appukkuttan S, Simmons S. Costs and healthcare resource utilization associated with hospital admissions of patients with metastatic or nonmetastatic prostate cancer. Am Heal Drug Benef. 2019;12:306\u201312.","journal-title":"Am Heal Drug Benef"},{"key":"2803_CR5","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1002\/cncr.34905","volume":"129","author":"M Horn\u00fd","year":"2023","unstructured":"Horn\u00fd M, Yabroff KR, Filson CP, et al. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance. Cancer. 2023;129:3252\u201362. https:\/\/doi.org\/10.1002\/cncr.34905.","journal-title":"Cancer"},{"key":"2803_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/13696998.2024.2303890","volume":"27","author":"DR Kaye","year":"2024","unstructured":"Kaye DR, Khilfeh I, Muser E, et al. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation. J Med Econ. 2024;27:201\u201314. https:\/\/doi.org\/10.1080\/13696998.2024.2303890.","journal-title":"J Med Econ"},{"key":"2803_CR7","doi-asserted-by":"publisher","first-page":"1419806","DOI":"10.3389\/fphar.2024.1419806","volume":"15","author":"NJ Kurganovs","year":"2024","unstructured":"Kurganovs NJ, Engedal N. To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics. Front Pharmacol. 2024;15:1419806. https:\/\/doi.org\/10.3389\/fphar.2024.1419806.","journal-title":"Front Pharmacol"},{"key":"2803_CR8","doi-asserted-by":"publisher","first-page":"55863","DOI":"10.18632\/oncotarget.10150","volume":"7","author":"AV Shubin","year":"2016","unstructured":"Shubin AV, Demidyuk IV, Komissarov AA, et al. Cytoplasmic vacuolization in cell death and survival. Oncotarget. 2016;7:55863\u201389. https:\/\/doi.org\/10.18632\/oncotarget.10150.","journal-title":"Oncotarget"},{"key":"2803_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41419-019-1360-4","volume":"10","author":"MJ Seo","year":"2019","unstructured":"Seo MJ, Lee DM, Kim IY, et al. Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis. Cell Death Dis. 2019;10:187. https:\/\/doi.org\/10.1038\/s41419-019-1360-4.","journal-title":"Cell Death Dis"},{"key":"2803_CR10","doi-asserted-by":"publisher","first-page":"1159409","DOI":"10.3389\/fphar.2023.1159409","volume":"14","author":"S Hanson","year":"2023","unstructured":"Hanson S, Dharan A, Jinsha PV, et al. Paraptosis: a unique cell death mode for targeting cancer. Front Pharmacol. 2023;14:1159409. https:\/\/doi.org\/10.3389\/fphar.2023.1159409.","journal-title":"Front Pharmacol"},{"key":"2803_CR11","doi-asserted-by":"publisher","first-page":"715285","DOI":"10.3389\/fphar.2021.715285","volume":"12","author":"S Wang","year":"2021","unstructured":"Wang S, Guo Y, Yang C, et al. Swainsonine triggers paraptosis via ER stress and MAPK signaling pathway in rat primary renal tubular epithelial cells. Front Pharmacol. 2021;12:715285. https:\/\/doi.org\/10.3389\/fphar.2021.715285.","journal-title":"Front Pharmacol"},{"key":"2803_CR12","doi-asserted-by":"publisher","first-page":"10420","DOI":"10.1038\/srep10420","volume":"5","author":"W-J Lee","year":"2015","unstructured":"Lee W-J, Chien M-H, Chow J-M, et al. Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species -mediated endoplasmic reticulum stress. Sci Rep. 2015;5:10420. https:\/\/doi.org\/10.1038\/srep10420.","journal-title":"Sci Rep"},{"key":"2803_CR13","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1038\/s41598-021-82381-3","volume":"11","author":"S Sharma","year":"2021","unstructured":"Sharma S, Ghufran SM, Ghose S, Biswas S. Cytoplasmic vacuolation with endoplasmic reticulum stress directs sorafenib induced non-apoptotic cell death in hepatic stellate cells. Sci Rep. 2021;11:3089. https:\/\/doi.org\/10.1038\/s41598-021-82381-3.","journal-title":"Sci Rep"},{"key":"2803_CR14","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1038\/onc.2009.118","volume":"28","author":"R Kar","year":"2009","unstructured":"Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene. 2009;28:2556\u201368. https:\/\/doi.org\/10.1038\/onc.2009.118.","journal-title":"Oncogene"},{"key":"2803_CR15","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1038\/cddis.2012.192","volume":"4","author":"PK Singha","year":"2013","unstructured":"Singha PK, Pandeswara S, Venkatachalam MA, Saikumar P. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis. 2013;4:e457. https:\/\/doi.org\/10.1038\/cddis.2012.192.","journal-title":"Cell Death Dis"},{"key":"2803_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","volume":"35","author":"M Mori","year":"2017","unstructured":"Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;35:556\u201365. https:\/\/doi.org\/10.1007\/s10637-017-0470-z.","journal-title":"Invest New Drugs"},{"key":"2803_CR17","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1111\/cas.15958","volume":"114","author":"C Ando","year":"2023","unstructured":"Ando C, Ichihara E, Nishi T, et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Cancer Sci. 2023;114:4343\u201354. https:\/\/doi.org\/10.1111\/cas.15958.","journal-title":"Cancer Sci"},{"key":"2803_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2767-9764.crc-21-0156","volume":"2","author":"RA Patel","year":"2022","unstructured":"Patel RA, Coleman I, Roudier MP, et al. Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations. Cancer Res Commun. 2022;2:277\u201385. https:\/\/doi.org\/10.1158\/2767-9764.crc-21-0156.","journal-title":"Cancer Res Commun"},{"key":"2803_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41419-024-07082-x","volume":"15","author":"C-Y Sun","year":"2024","unstructured":"Sun C-Y, Cao D, Wang Y-N, et al. Cholesterol inhibition enhances antitumor response of gilteritinib in lung cancer cells. Cell Death Dis. 2024;15:704. https:\/\/doi.org\/10.1038\/s41419-024-07082-x.","journal-title":"Cell Death Dis"},{"key":"2803_CR20","doi-asserted-by":"publisher","first-page":"829759","DOI":"10.3389\/fphar.2022.829759","volume":"13","author":"C-Y Sun","year":"2022","unstructured":"Sun C-Y, Talukder M, Cao D, Chen C-W. Gilteritinib enhances anti-tumor efficacy of CDK4\/6 inhibitor, Abemaciclib in lung cancer cells. Front Pharmacol. 2022;13:829759. https:\/\/doi.org\/10.3389\/fphar.2022.829759.","journal-title":"Front Pharmacol"},{"key":"2803_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41467-021-21396-w","volume":"12","author":"H Mizuta","year":"2021","unstructured":"Mizuta H, Okada K, Araki M, et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nat Commun. 2021;12:1261. https:\/\/doi.org\/10.1038\/s41467-021-21396-w.","journal-title":"Nat Commun"},{"key":"2803_CR22","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/jcmm.14913","volume":"24","author":"L Li","year":"2020","unstructured":"Li L, Lin L, Li M, Li W. Gilteritinib induces PUMA-dependent apoptotic cell death via AKT\/GSK-3\u03b2\/NF-\u03baB pathway in colorectal cancer cells. J Cell Mol Med. 2020;24:2308\u201318. https:\/\/doi.org\/10.1111\/jcmm.14913.","journal-title":"J Cell Mol Med"},{"key":"2803_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00277-021-04516-w","volume":"101","author":"T Onaka","year":"2022","unstructured":"Onaka T, Kato-Ogura A, Otsuka Y, et al. A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer. Ann Hematol. 2022;101:457\u20138.","journal-title":"Ann Hematol"},{"key":"2803_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41420-025-02417-9","volume":"11","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Hu R, Liu J, et al. Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors. Cell Death Discov. 2025;11:124. https:\/\/doi.org\/10.1038\/s41420-025-02417-9.","journal-title":"Cell Death Discov"},{"key":"2803_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","volume":"1","author":"V Vichai","year":"2006","unstructured":"Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112\u20136. https:\/\/doi.org\/10.1038\/nprot.2006.179.","journal-title":"Nat Protoc"},{"key":"2803_CR26","first-page":"3","volume":"66","author":"A Biederbick","year":"1995","unstructured":"Biederbick A, Kern HF, Els\u00e4sser HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol. 1995;66:3\u201314.","journal-title":"Eur J Cell Biol"},{"key":"2803_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.annepidem.2023.01.004","volume":"79","author":"BF Drake","year":"2023","unstructured":"Drake BF, Khan S, Wang M, et al. Definitive treatment and risk of death among men diagnosed with metastatic prostate cancer at the veterans health administration. Ann Epidemiol. 2023;79:24\u201331. https:\/\/doi.org\/10.1016\/j.annepidem.2023.01.004.","journal-title":"Ann Epidemiol"},{"key":"2803_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/cancers6031298","volume":"6","author":"Y Gong","year":"2014","unstructured":"Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014;6:1298\u2013327. https:\/\/doi.org\/10.3390\/cancers6031298.","journal-title":"Cancers (Basel)"},{"key":"2803_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341\u201352. https:\/\/doi.org\/10.1038\/s41580-020-0237-9.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2803_CR30","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773. https:\/\/doi.org\/10.1016\/j.tranon.2020.100773.","journal-title":"Transl Oncol"},{"key":"2803_CR31","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461\u201373. https:\/\/doi.org\/10.1038\/onc.2016.304.","journal-title":"Oncogene"},{"key":"2803_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X. Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13:165. https:\/\/doi.org\/10.1186\/s13045-020-00990-3.","journal-title":"J Hematol Oncol"},{"key":"2803_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/cyto.a.22495","volume":"85","author":"A Pierzy\u0144ska-Mach","year":"2014","unstructured":"Pierzy\u0144ska-Mach A, Janowski PA, Dobrucki JW. Evaluation of acridine orange, LysoTracker Red, and quinacrine as fluorescent probes for long-term tracking of acidic vesicles. Cytom Part A J Int Soc Anal Cytol. 2014;85:729\u201337. https:\/\/doi.org\/10.1002\/cyto.a.22495.","journal-title":"Cytom Part A J Int Soc Anal Cytol"},{"key":"2803_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1089\/ars.2014.5851","volume":"21","author":"SS Cao","year":"2014","unstructured":"Cao SS, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal. 2014;21:396\u2013413. https:\/\/doi.org\/10.1089\/ars.2014.5851.","journal-title":"Antioxid Redox Signal"},{"key":"2803_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s12276-021-00560-8","volume":"53","author":"KR Bhattarai","year":"2021","unstructured":"Bhattarai KR, Riaz TA, Kim H-R, Chae H-J. The aftermath of the interplay between the endoplasmic reticulum stress response and redox signaling. Exp Mol Med. 2021;53:151\u201367. https:\/\/doi.org\/10.1038\/s12276-021-00560-8.","journal-title":"Exp Mol Med"},{"key":"2803_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","volume":"8","author":"X Chen","year":"2023","unstructured":"Chen X, Shi C, He M, et al. Endoplasmic reticulum stress: molecular mechanism and therapeutic targets. Signal Transduct Target Ther. 2023;8:352. https:\/\/doi.org\/10.1038\/s41392-023-01570-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2803_CR37","doi-asserted-by":"publisher","first-page":"932510","DOI":"10.3389\/fcell.2022.932510","volume":"10","author":"CW Molter","year":"2022","unstructured":"Molter CW, Muszynski EF, Tao Y, et al. Prostate cancer cells of increasing metastatic potential exhibit diverse contractile forces, cell stiffness, and motility in a microenvironment stiffness-dependent manner. Front cell Dev Biol. 2022;10:932510. https:\/\/doi.org\/10.3389\/fcell.2022.932510.","journal-title":"Front cell Dev Biol"},{"key":"2803_CR38","doi-asserted-by":"publisher","first-page":"17216","DOI":"10.18632\/oncotarget.15303","volume":"8","author":"SK Singh","year":"2017","unstructured":"Singh SK, Banerjee S, Acosta EP, et al. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53\/ p21WAF1\/CIP1 and p27KIP1 pathway. Oncotarget. 2017;8:17216\u201328. https:\/\/doi.org\/10.18632\/oncotarget.15303.","journal-title":"Oncotarget"},{"key":"2803_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74\u201388. https:\/\/doi.org\/10.1038\/s41580-021-00404-3.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2803_CR40","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/sj.leu.2404923","volume":"21","author":"T Kajiguchi","year":"2007","unstructured":"Kajiguchi T, Chung EJ, Lee S, et al. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia. 2007;21:2476\u201384. https:\/\/doi.org\/10.1038\/sj.leu.2404923.","journal-title":"Leukemia"},{"key":"2803_CR41","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","volume":"81","author":"K Unno","year":"2021","unstructured":"Unno K, Chalmers ZR, Pamarthy S, et al. Activated ALK cooperates with N-Myc via Wnt\/\u03b2-Catenin signaling to induce neuroendocrine prostate cancer. Cancer Res. 2021;81:2157\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3351.","journal-title":"Cancer Res"},{"key":"2803_CR42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12885-021-08450-y","volume":"21","author":"M Fatima","year":"2021","unstructured":"Fatima M, Kakar SJ, Adnan F, et al. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia. BMC Cancer. 2021;21:713. https:\/\/doi.org\/10.1186\/s12885-021-08450-y.","journal-title":"BMC Cancer"},{"key":"2803_CR43","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1074\/jbc.REV118.002804","volume":"294","author":"KFR Pobre","year":"2019","unstructured":"Pobre KFR, Poet GJ, Hendershot LM. The endoplasmic reticulum (ER) chaperone BiP is a master regulator of ER functions: getting by with a little help from ERdj friends. J Biol Chem. 2019;294:2098\u2013108. https:\/\/doi.org\/10.1074\/jbc.REV118.002804.","journal-title":"J Biol Chem"},{"issue":"3","key":"2803_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/cells12030403","volume":"12","author":"T Paskevicius","year":"2023","unstructured":"Paskevicius T, Farraj RA, Michalak M, Agellon LB. Calnexin, more than just a molecular Chaperone. Cells. 2023;12(3):403. https:\/\/doi.org\/10.3390\/cells12030403.","journal-title":"Cells"},{"key":"2803_CR45","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/febs.13598","volume":"283","author":"R Iurlaro","year":"2016","unstructured":"Iurlaro R, Mu\u00f1oz-Pinedo C. Cell death induced by endoplasmic reticulum stress. FEBS J. 2016;283:2640\u201352. https:\/\/doi.org\/10.1111\/febs.13598.","journal-title":"FEBS J"},{"key":"2803_CR46","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/bcr2934","volume":"13","author":"M Wennemers","year":"2011","unstructured":"Wennemers M, Bussink J, Scheijen B, et al. Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Res. 2011;13:R82. https:\/\/doi.org\/10.1186\/bcr2934.","journal-title":"Breast Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02803-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02803-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02803-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:40:00Z","timestamp":1751532000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02803-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2803"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02803-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work, the author(s) used ChatGPT to improve the readability and language of the manuscript. After using this tool\/service, the author(s) reviewed and edited the content as needed and took full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"241"}}